Greehey CCRI ZOOMinar Series Presents: Marielle E. Yohe, MD, PhD – NIH, Pediatric Oncology Branch
Event Date & TimeSeptember 17, 2021
LocationZOOM Meeting ID: 914 0902 1393
Presentation Title: “Combined MEK and IGF2 inhibition in RAS mutant pediatric solid tumors”
Greehey CCRI Host: Angelina Vaseva, PhD
Join Zoom Meeting@ 11:00am CST
Meeting ID: 914 0902 1393
11:00pm – 12:00pm CST SEMINAR
Save to CalendarAdd to Calendar
About the Speaker(s)
More than 30% of all human malignancies are driven by mutant RAS isoforms. In addition to well-characterized roles in malignant transformation and tumor progression, oncogenic RAS is also able to block differentiation within a cancer cell. We have previously shown that inhibiting the RAS-RAF-MEK-ERK MAP kinase pathway restores the differentiation of rhabdomyosarcoma cells by affecting the transcription of the master transcription factor, MYOG. Current laboratory projects include characterizing the effect of oncogenic RAS on the differentiation of neuroblastoma cells and identifying mechanisms by which rhabdomyosarcoma cells acquire resistance to MAP kinase pathway inhibitors. In addition, the laboratory is engaged in translational research aimed at identifying additional RAS-directed therapeutics for pediatric cancers.
NIH Scientific Focus Areas:
Since 2004, UT Health San Antonio, Greehey Children’s Cancer Research Institute’s (Greehey CCRI) mission has been to advance scientific knowledge relevant to childhood cancer, contribute to the understanding of its causes, and accelerate the translation of knowledge into novel therapies. Through discovery, development, and dissemination of new scientific knowledge, Greehey CCRI strives to have a national and global impact on childhood cancer. Our mission consists of three key areas — research, clinical, and education.